
Phase 1 Study with Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants with Mesothelin-Expressing Solid Tumors Including Mesothelioma
Researchers at NCI are developing a new investigational treatment known as TNhYP218 CAR T cells to target and kill tumor cells in people with solid tumors and with those that have high levels of mesothelin (MSLN) including mesothelioma. The study team collects immune cells (T cells); the T cells are genetically modified to target and kill tumor cells to potentially shrink the tumor.

Evaluation for NCI Surgery Branch Clinical Research Protocols
Doctors at the National Cancer Institute (NCI) are looking for volunteers with metastatic cancers, including breast, ovarian, endometrial, gastrointestinal, genitourinary, hepatobiliary, pancreatic, melanoma, non-small cell lung cancer (NSCLC), and multiple myeloma with solid masses. Potential participants will be evaluated with new immunotherapy treatments utilizing cell transfer immunotherapies in a research trial.

CAR-T Cell Treatment for Patients with Glypican-3 (GPC3) Positive HCC (A Type of Liver Cancer)

Men at High Genetic Risk for Prostate Cancer

Phase II Trial Evaluating Nivolumab in Patients with IDH-Mutant Gliomas with and without Hypermutator Phenotype
National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

A Phase II Study of Combined Treatment of Durvalumab, Bevacizuamab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC)or Biliary Tract Carcinoma (BTC)

Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
National Cancer Institute (NCI) researchers are conducting a study of patients with rare central nervous system (CNS) tumors. More than 130 primary rare CNS (brain or spine) tumors have been identified. Most affect less than 2,000 people in the United States each year. This study will test whether stimulating the immune system using the drug nivolumab can shrink select rare brain or spine tumors or increase the time it takes for them to grow or spread.

18F-DCFPyL PET/CT in Hepatocellular Carcinoma
